Valeo Financial Advisors LLC Buys 3,144 Shares of Boston Scientific Corporation (NYSE:BSX)

Valeo Financial Advisors LLC boosted its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 17.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 21,621 shares of the medical equipment provider's stock after purchasing an additional 3,144 shares during the quarter. Valeo Financial Advisors LLC's holdings in Boston Scientific were worth $2,180,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after purchasing an additional 226 shares during the last quarter. Bank Pictet & Cie Europe AG grew its position in shares of Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after purchasing an additional 21,173 shares during the last quarter. Highview Capital Management LLC DE boosted its position in Boston Scientific by 6.2% during the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after acquiring an additional 1,439 shares during the last quarter. Proficio Capital Partners LLC boosted its position in Boston Scientific by 40.2% during the fourth quarter. Proficio Capital Partners LLC now owns 5,333 shares of the medical equipment provider's stock worth $476,000 after acquiring an additional 1,528 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC raised its stake in Boston Scientific by 2.3% during the fourth quarter. Ashton Thomas Private Wealth LLC now owns 5,945 shares of the medical equipment provider's stock worth $531,000 after purchasing an additional 136 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Up 0.9%

Shares of NYSE BSX traded up $0.97 during trading on Thursday, hitting $103.93. 2,386,924 shares of the company traded hands, compared to its average volume of 7,629,843. The business's fifty day moving average is $103.45 and its 200 day moving average is $100.35. Boston Scientific Corporation has a fifty-two week low of $71.88 and a fifty-two week high of $107.53. The firm has a market capitalization of $153.75 billion, a price-to-earnings ratio of 75.86, a P/E/G ratio of 2.66 and a beta of 0.68. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.88 and a current ratio of 1.45.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The firm had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same period in the prior year, the firm earned $0.56 EPS. The company's revenue was up 20.9% compared to the same quarter last year. Equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Michael F. Mahoney sold 164,443 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the completion of the sale, the chief executive officer directly owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. The trade was a 10.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP John Bradley Sorenson sold 4,572 shares of the company's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $104.54, for a total transaction of $477,956.88. Following the completion of the transaction, the executive vice president owned 18,705 shares of the company's stock, valued at approximately $1,955,420.70. The trade was a 19.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 461,970 shares of company stock worth $47,755,193. 0.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Morgan Stanley lifted their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, May 16th. Wall Street Zen raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Leerink Partners initiated coverage on shares of Boston Scientific in a research note on Monday, June 16th. They issued an "outperform" rating and a $118.00 price objective for the company. Evercore ISI increased their price objective on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Finally, Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Twenty-two equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $116.09.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.